Alligator Bioscience AB

Alligator Bioscience AB has a negative net equity of -9.51 million SEK, indicating a significant deficit in its capital structure. The company's liquidity position is weak, with a current ratio of 0.67, suggesting it may struggle to meet short-term obligations. Despite holding 77.51 million SEK in cash and equivalents, the company's operating cash flow is negative at -120.98 million SEK, reflecting ongoing operational challenges.

Profitability metrics show a return on equity of 5.17, which is unusually high given the negative equity, and a return on assets of -0.41, indicating poor asset utilization. These figures are not directly comparable to industry medians due to the absence of industry_config data for this company. However, the negative operating income of -47.38 million SEK and net loss of -49.21 million SEK highlight the company's unprofitable operations.

The company's revenue is not segmented by product or geographic region in the provided data, making it difficult to assess revenue concentration or geographic exposure. The lack of segment data prevents a detailed analysis of the company's diversification or risk from over-reliance on specific markets or products.

Looking ahead, the company is projected to continue its current trajectory, with no specific growth metrics provided in the outlook. The absence of capital expenditures and the negative free cash flow of -46.93 million SEK suggest the company is not investing in new projects and is relying on existing cash reserves to sustain operations.

Risk factors include a low liquidity score and the potential for dilution, although no immediate filing-based liquidity or dilution flags were detected. The company's dilution potential is currently assessed as low, and no adjustments have been applied to the valuation metrics. The absence of capital expenditures and the negative operating cash flow are key indicators of the company's financial health.

Recent events, as reflected in the financial data, show a consistent pattern of losses and negative cash flows. The company has not issued any new shares recently, and there are no indications of significant changes in its financial strategy or operations. The lack of analyst price targets and the single "hold" recommendation suggest limited investor confidence in the company's near-term prospects.

Revenue grew 45.3% annually over four years, demonstrating strong top-line expansion momentum for the biotechnology company.

Analysts project 530.3% upside to a target price of 0.3 SEK, indicating significant potential valuation appreciation.

Return on equity of 5.17% ranks best-in-class among 582 biotechnology peers, highlighting superior capital efficiency.

Cash conversion ratio of 2.46 is best-in-class, suggesting efficient management of cash flows relative to earnings.

Low dilution, liquidity, and credit risk flags suggest a stable financial foundation despite ongoing operational losses.

Operating margin of -6.25% falls below the cohort median of -2.61%, reflecting inferior cost management.

Return on invested capital is negative at -20.77%, showing the company destroys value on deployed capital.

Book value is negative at -9.5 million SEK, indicating accumulated losses exceed total assets on the balance sheet.

Revenue kr 514.0k, −99,1% YoY; Operating income +54,9% YoY.

• ▍Revenue kr 514.0k, −99,1% YoY
• ▍Operating income +54,9% YoY
• ▍Net income +78,0% YoY
• ▍Free cash flow +77,3% YoY
• ▍Net margin -9990.3%

Revenue kr 58.1M, +62,8% YoY; Operating income −29,1% YoY.

• ▍Revenue kr 58.1M, +62,8% YoY
• ▍Operating income −29,1% YoY
• ▍Net income −28,5% YoY
• ▍Free cash flow −31,9% YoY
• ▍Net margin -427.8%

Revenue kr 35.7M, +175,8% YoY; Operating income −36,2% YoY.

• ▍Revenue kr 35.7M, +175,8% YoY
• ▍Operating income −36,2% YoY
• ▍Net income −36,5% YoY
• ▍Free cash flow −41,0% YoY
• ▍Net margin -541.8%

Revenue kr 12.9M; Operating income -kr 141.6M.

• ▍Revenue kr 12.9M
• ▍Operating income -kr 141.6M
• ▍Net margin -1095.1%